Health Evaluation of Abilify Long-term Therapy (HEALTH)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. The health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.
Condition or disease
Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients between the ages of 18 to 65.
Having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder.
Who are currently taking antipsychotic drugs and clinically intolerable or inadequately controlled that is based upon the clinical judgment of the investigator.
Pregnant or breast feeding women or planning a pregnancy.
Patient received electroconvulsive therapy within 4 weeks before the Screening Visit.
A known allergy reaction to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone).
Patient has clinically relevant organic, neurological, or cardiovascular diseases.
Patient has a history of drug or alcohol abuse within the last 12 weeks.
Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention.
Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.
Having participated other investigational drug study and taken the investigation drug within one month prior to study entry.
Depot neuroleptics should be discontinued at least 2 months prior to enrollment.